Tinlarebant

N/A

Report date: 2026/05/20 17:55:34
NME

Base Information

Drug NameTinlarebant
Drug Alias NameLBS-008BPN-14967LBS-008re
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionRetinol-binding protein 4 inhibitors
TargetsRetinol-binding protein 4
Therapy Area/IndicationsGeographic AtrophyMacular DegenerationStargardt Disease
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryCzechiaBelgiumUnited States +[13] 
CombinationsNo
Global Highest StatusNDA/BLA
Highest Status in ChinaNDA/BLA
Originator CompaniesColumbia University
China Registration ClassClass 1 Chemical Drug in China

Develop Information

Active CompaniesBelite Bio IncLin Bioscience IncBeiliang Bio-Pharmaceutical (Shanghai) Co Ltd +[5] 
Inactive CompaniesN/A
Active IndicationsGeographic AtrophyMacular DegenerationStargardt Disease
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksDrugBankKEGG